z-logo
open-access-imgOpen Access
Platelet EVs contain an active proteasome involved in protein processing for antigen presentation via MHC-I molecules
Author(s) -
Geneviève Marcoux,
Audrée Laroche,
Stephan Hasse,
Marie Bellio,
Maroua Mbarik,
Marie Tamagne,
Isabelle Allaeys,
Anne Zufferey,
Tania Lévesque,
Johan Rebetz,
Annie Karakeussian-Rimbaud,
Julie Turgeon,
Sylvain Bourgoin,
Hind HamzehCognasse,
Fabrice Cognasse,
Rick Kapur,
John W. Semple,
MarieJosée Hébert,
France Pirenne,
Herman S. Overkleeft,
Bogdan I. Florea,
Mélanie Dieudé,
Benoît Vingert,
Éric Boilard
Publication year - 2021
Publication title -
blood
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.515
H-Index - 465
eISSN - 1528-0020
pISSN - 0006-4971
DOI - 10.1182/blood.2020009957
Subject(s) - platelet , antigen presentation , antigen processing , antigen , mhc class i , biology , immune system , immunology , cd8 , major histocompatibility complex , cross presentation , microbiology and biotechnology , t cell
In addition to their hemostatic role, platelets play a significant role in immunity. Once activated, platelets release extracellular vesicles (EVs) formed by the budding of their cytoplasmic membranes. Because of their heterogeneity, platelet EVs (PEVs) are thought to perform diverse functions. It is unknown, however, whether the proteasome is transferred from platelets to PEVs or whether its function is retained. We hypothesized that functional protein processing and antigen presentation machinery are transferred to PEVs by activated platelets. Using molecular and functional assays, we found that the active 20S proteasome was enriched in PEVs, along with major histocompatibility complex class I (MHC-I) and lymphocyte costimulatory molecules (CD40L and OX40L). Proteasome-containing PEVs were identified in healthy donor blood, but did not increase in platelet concentrates that caused adverse transfusion reactions. They were augmented, however, after immune complex injections in mice. The complete biodistribution of murine PEVs after injection into mice revealed that they principally reached lymphoid organs, such as spleen and lymph nodes, in addition to the bone marrow, and to a lesser extent, liver and lungs. The PEV proteasome processed exogenous ovalbumin (OVA) and loaded its antigenic peptide onto MHC-I molecules, which promoted OVA-specific CD8+ T-lymphocyte proliferation. These results suggest that PEVs contribute to adaptive immunity through cross-presentation of antigens and have privileged access to immune cells through the lymphatic system, a tissue location that is inaccessible to platelets.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom